SG11201604501TA - Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer - Google Patents
Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancerInfo
- Publication number
- SG11201604501TA SG11201604501TA SG11201604501TA SG11201604501TA SG11201604501TA SG 11201604501T A SG11201604501T A SG 11201604501TA SG 11201604501T A SG11201604501T A SG 11201604501TA SG 11201604501T A SG11201604501T A SG 11201604501TA SG 11201604501T A SG11201604501T A SG 11201604501TA
- Authority
- SG
- Singapore
- Prior art keywords
- estrogen receptor
- treatment
- breast cancer
- locally advanced
- positive breast
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913167P | 2013-12-06 | 2013-12-06 | |
| US201461981672P | 2014-04-18 | 2014-04-18 | |
| PCT/IB2014/002679 WO2015082990A1 (en) | 2013-12-06 | 2014-12-05 | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201604501TA true SG11201604501TA (en) | 2016-07-28 |
Family
ID=52347358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604501TA SG11201604501TA (en) | 2013-12-06 | 2014-12-05 | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9675586B2 (en) |
| EP (1) | EP3089747A1 (en) |
| JP (1) | JP2016540767A (en) |
| KR (1) | KR20160085915A (en) |
| CN (1) | CN105916501A (en) |
| AU (1) | AU2014358850A1 (en) |
| CA (1) | CA2932106A1 (en) |
| HK (1) | HK1223557A1 (en) |
| IL (1) | IL245758A0 (en) |
| MX (1) | MX2016007282A (en) |
| SG (1) | SG11201604501TA (en) |
| WO (1) | WO2015082990A1 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| SG10201912719TA (en) | 2012-09-26 | 2020-02-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| US9586952B2 (en) | 2013-03-14 | 2017-03-07 | Genentech, Inc. | Polycyclic estrogen receptor modulators and uses thereof |
| CA2912853A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator and uses thereof |
| BR112015030595A2 (en) | 2013-06-19 | 2017-07-25 | Seragon Pharmaceuticals Inc | azetidine estrogen receptor modulators and uses thereof |
| JP2017509631A (en) | 2014-03-13 | 2017-04-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Methods and compositions for modulating estrogen receptor mutants |
| US20180173846A1 (en) * | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| KR20170040251A (en) | 2014-08-11 | 2017-04-12 | 에프. 호프만-라 로슈 아게 | Crystalline forms of an estrogen receptor modulator |
| PT3233852T (en) | 2014-12-18 | 2020-09-10 | Hoffmann La Roche | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof |
| US9845291B2 (en) | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
| EP3303326B1 (en) | 2015-05-26 | 2020-12-16 | H. Hoffnabb-La Roche Ag | Heterocyclic estrogen receptor modulators and uses thereof |
| WO2017060326A1 (en) | 2015-10-07 | 2017-04-13 | F. Hoffmann-La Roche Ag | Process for the preparation of (e)-3-(4-((e)-2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid |
| JP6592197B2 (en) | 2015-11-12 | 2019-10-16 | 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． | Acrylic acid derivatives, process for preparation and use thereof as pharmaceuticals |
| BR112018070161A2 (en) | 2016-04-01 | 2019-02-12 | Zeno Royalties & Milestones, LLC | estrogen receptor modulators |
| US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| CN110799183A (en) * | 2017-06-20 | 2020-02-14 | 癌症研究所：皇家癌症医院 | Method and medical use |
| SG11202003402QA (en) | 2017-10-16 | 2020-05-28 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| EP3498273A1 (en) * | 2017-12-14 | 2019-06-19 | Universität Wien | Pharmaceutical composition for modulating the response of a gaba-a receptor |
| CA3098601A1 (en) * | 2018-05-02 | 2019-11-07 | Estetra Sprl | Treatment of advanced estrogen receptor positive breast cancer |
| CA3098203A1 (en) | 2018-06-21 | 2019-12-26 | F. Hoffmann-La Roche Ag | Tartrate salt of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and crystal forms thereof |
| ES2924738T3 (en) | 2018-09-07 | 2022-10-10 | Sanofi Sa | Process for the preparation of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo Methyl [7]annulene-2-carboxylate and a salt thereof |
| WO2020225375A1 (en) * | 2019-05-09 | 2020-11-12 | Sanofi | 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients |
| US20220220107A1 (en) | 2019-05-24 | 2022-07-14 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Crystal forms of acrylic acid derivatives, preparation method therefor and use thereof |
| BR112022002138A2 (en) | 2019-08-06 | 2022-04-19 | Recurium Ip Holdings Llc | Estrogen receptor modulators for treatment of mutants |
| WO2022140744A1 (en) | 2020-12-23 | 2022-06-30 | Recurium Ip Holdings, Llc | Estrogen receptor modulators |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| PE20142461A1 (en) | 2012-03-20 | 2015-02-05 | Seragon Pharmaceuticals Inc | ESTROGEN RECEPTOR MODULATORS AND THEIR USES |
| US9586952B2 (en) | 2013-03-14 | 2017-03-07 | Genentech, Inc. | Polycyclic estrogen receptor modulators and uses thereof |
-
2014
- 2014-12-05 EP EP14827261.0A patent/EP3089747A1/en not_active Withdrawn
- 2014-12-05 CN CN201480066547.XA patent/CN105916501A/en active Pending
- 2014-12-05 AU AU2014358850A patent/AU2014358850A1/en not_active Abandoned
- 2014-12-05 US US14/561,701 patent/US9675586B2/en not_active Expired - Fee Related
- 2014-12-05 KR KR1020167017951A patent/KR20160085915A/en not_active Application Discontinuation
- 2014-12-05 WO PCT/IB2014/002679 patent/WO2015082990A1/en active Application Filing
- 2014-12-05 SG SG11201604501TA patent/SG11201604501TA/en unknown
- 2014-12-05 MX MX2016007282A patent/MX2016007282A/en unknown
- 2014-12-05 CA CA2932106A patent/CA2932106A1/en not_active Abandoned
- 2014-12-05 JP JP2016536557A patent/JP2016540767A/en active Pending
-
2016
- 2016-05-22 IL IL245758A patent/IL245758A0/en unknown
- 2016-10-14 HK HK16111865.1A patent/HK1223557A1/en unknown
-
2017
- 2017-05-08 US US15/589,391 patent/US10034860B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HK1223557A1 (en) | 2017-08-04 |
| JP2016540767A (en) | 2016-12-28 |
| WO2015082990A1 (en) | 2015-06-11 |
| CA2932106A1 (en) | 2015-06-11 |
| US9675586B2 (en) | 2017-06-13 |
| MX2016007282A (en) | 2016-09-07 |
| EP3089747A1 (en) | 2016-11-09 |
| IL245758A0 (en) | 2016-07-31 |
| CN105916501A (en) | 2016-08-31 |
| US10034860B2 (en) | 2018-07-31 |
| KR20160085915A (en) | 2016-07-18 |
| AU2014358850A1 (en) | 2016-06-16 |
| US20170239219A1 (en) | 2017-08-24 |
| WO2015082990A8 (en) | 2016-07-21 |
| AU2014358850A8 (en) | 2016-08-04 |
| US20150157606A1 (en) | 2015-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1223557A1 (en) | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer | |
| HUS2400002I1 (en) | Treating breast cancer using selective estrogen receptor modulators | |
| IL237558A0 (en) | Methods for the treatment of locally advanced breast cancer | |
| IL245196A0 (en) | Specific anti-cd38 antibodies for treating human cancers | |
| IL245731A0 (en) | Combination therapy for treating cancer | |
| PT3033086T (en) | Combination therapy for the treatment of cancer | |
| EP2968343A4 (en) | Combination therapy for treating cancer | |
| HK1222869A1 (en) | Conjugated antibodies against ly75 for the treatment of cancer ly75 | |
| HK1222548A1 (en) | Pharmaceutical combinations for the treatment of cancer | |
| HK1219737A1 (en) | Novel compounds for the treatment of cancer | |
| HK1213909A1 (en) | Melk regulation for the treatment of breast cancer melk | |
| IL281541A (en) | Specific anti-cd38 antibodies for treating human cancers | |
| HK1223547A1 (en) | Methods for the treatment of cancer | |
| IL245551A0 (en) | Antibodies anti matriptase for the treatment of cancer | |
| PL3016948T3 (en) | 2-acylaminothiazoles for the treatment of cancer | |
| EP3077812A4 (en) | Methods for the prognosis of breast cancer | |
| GB201321531D0 (en) | Treatment for cancers | |
| AP2015008905A0 (en) | Novel compounds for the treatment of cancer | |
| GB201300546D0 (en) | Cancer Treatment |